Vol.56 No.S-1 April 2008
Clinical study of sitafloxacin in treatment of cervicitis with Chlamydia trachomatis
1)Japanese Foundation of Sexual Health Medicine, Hongo 3-14-10 Bunkyo-ku, Tokyo, Japan
2)Department of Obstetrics and Gynecology, Aichi Medical University
3)Department of Obstetrics and Gynecology, Matsushita Memorial Hospital
4)Department of Pharmacology, Jikei University School of Medicine
Abstract
The clinical efficacy and safety of sitafloxacin(STFX), a new quinolone compound, were evaluated in patients with cervicitis with Chlamydia trachomatis. STFX was administered orally at 50 mg twice a day for 7 days.
Overall clinical efficacy was 97.5% (39/40) in cervicitis. Eradication in microbiological outcome for C. trachomatis was 97.5% (39/40). Cure at the end of treatment was 32.5% (13/40) and at 1-2 weeks after the end of treatment was 47.5% (19/40).
Adverse reactions occurred in 23.3% (10/43) of cases evaluable for safety, the most common being diarrhoea at an incidence of 9.3% (4/43). All symptoms were mild or moderate.
Results suggest that STFX is effective and safe in the treatment of cervicitis with C. trachomatis.
Key word
sitafloxacin, cervicitis, Chlamydia trachomatis, clinical trial
Received
November 2, 2007
Accepted
November 14, 2007
Jpn. J. Chemother. 56 (S-1): 139-145, 2008
